15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering MaxCyte Inc, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $5.00 to $5.00, so the covering firms are broadly aligned. The average target of $5.00 sits 390% above the current $1.02. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.23 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Hold
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to MaxCyte Inc.
As of Jul, 1 of 3 firms rate MXCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MXCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 3 analysts · -9% YoY
Next period, 3 analysts expect MaxCyte Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $-0.09 a year earlier. Full-year consensus is $-0.28, growing to $-0.23 the year after.
REVENUE · NEXT QUARTER
$7.0M
Range $6.4M – $7.2M · 3 analysts · +2% YoY
Revenue is expected to reach $7.0M (range $6.4M – $7.2M), +1.8% year-over-year. Full-year consensus is $31.1M, rising to $37.1M next year.
Top analysts covering MaxCyte Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MXCT.
#1
BS
Brendan Smith
TD Cowen
Buy
No targeton MXCT
Coverage
—
+ Follow
#2
MH
Matt Hewitt
Craig-Hallum
Buy
$5.00+390.2% to target
Coverage
—
+ Follow
#3
HH
Helfey Hannah
Stephens & Co.
Buy
$6.00+488.2% to target
Coverage
—
+ Follow
MXCT stock forecast FAQ
What is MXCT's average 12-month price target?+
The 1 analysts with a live target average $5.00 for MaxCyte Inc over the next 12 months, ranging from a $5.00 high to a $5.00 low.
Is MXCT stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover MXCT?+
3 analysts have an active rating on MaxCyte Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering MXCT?+
Among analysts who currently cover MXCT, Brendan Smith of TD Cowen has the strongest overall Quantellect track record. Their current call is Buy.
What is MaxCyte Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 3 analysts. Full-year EPS is projected at $-0.28, rising to $-0.23 the following year.
How much revenue is MaxCyte Inc expected to report next quarter?+
Consensus revenue is $7.0M (range $6.4M – $7.2M). Full-year revenue is projected at $31.1M, growing to $37.1M next year.
Have analysts been upgrading or downgrading MXCT lately?+
As of Jul, 1 of 3 firms rate MXCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MXCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
